Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATG7 RNAi
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal, Intrathecal, Intranasal, Parenteral, Oral
01
Overview
ATG7 RNAi refers to RNA interference-based approaches (such as small interfering RNAs or short hairpin RNAs) designed to knock down the expression of Autophagy-related protein 7 (ATG7). ATG7 is an essential E1-like activating enzyme required for the ubiquitin-like conjugation systems that drive autophagosome biogenesis and macroautophagy. In preclinical oncology research, silencing ATG7 via RNAi has been shown to inhibit protective autophagy, thereby sensitizing cancer cells (such as estrogen receptor-positive breast cancer, pancreatic cancer, and osteosarcoma) to chemotherapy and endocrine therapies. Additionally, ATG7 knockdown has been investigated for its role in modulating immune cell recruitment, cytokine profiles, and viral replication in infectious disease models.
- Other names
- ATG7 shRNAATG-7 shRNAATG 7 shRNAATG7 siRNAATG-7 siRNAATG 7 siRNAAtg7 RNAiAtg-7 RNAiAtg 7 RNAi
02
Targets
ATG7 (Ubiquitin-like modifier-activating enzyme ATG7)
Beyond the preview
Go deeper on ATG7 RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATG7 RNAi.